EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Thomas Huang; Brigitte J Engelmann; Rachael M Morgan; Kimberly J Absher; Jill M Kolesar; John L Villano

doi:10.1007/s00280-018-3571-2

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Thomas Huang, Brigitte J Engelmann, Rachael M Morgan, Kimberly J Absher, Jill M Kolesar, John L Villano

Research output: Contribution to journal › Article › peer-review

Abstract

EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.

Original language	English
Pages (from-to)	965-968
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	81
Issue number	5
DOIs	https://doi.org/10.1007/s00280-018-3571-2
State	Published - May 2018

Keywords

Carbazoles/pharmacology
Carcinoma, Squamous Cell/drug therapy
Crizotinib/pharmacology
Genetic Testing
Humans
Lung Neoplasms/drug therapy
Male
Middle Aged
Oncogene Proteins, Fusion/antagonists & inhibitors
Patient Selection
Piperidines/pharmacology
Smoking/adverse effects
Treatment Outcome

Access to Document

10.1007/s00280-018-3571-2

Cite this

@article{bedabb1db8284022849674bc6fa8a290,

title = "EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib",

abstract = "EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.",

keywords = "Carbazoles/pharmacology, Carcinoma, Squamous Cell/drug therapy, Crizotinib/pharmacology, Genetic Testing, Humans, Lung Neoplasms/drug therapy, Male, Middle Aged, Oncogene Proteins, Fusion/antagonists & inhibitors, Patient Selection, Piperidines/pharmacology, Smoking/adverse effects, Treatment Outcome",

author = "Thomas Huang and Engelmann, {Brigitte J} and Morgan, {Rachael M} and Absher, {Kimberly J} and Kolesar, {Jill M} and Villano, {John L}",

year = "2018",

month = may,

doi = "10.1007/s00280-018-3571-2",

language = "English",

volume = "81",

pages = "965--968",

number = "5",

}

TY - JOUR

T1 - EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

AU - Huang, Thomas

AU - Engelmann, Brigitte J

AU - Morgan, Rachael M

AU - Absher, Kimberly J

AU - Kolesar, Jill M

AU - Villano, John L

PY - 2018/5

Y1 - 2018/5

N2 - EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.

AB - EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.

KW - Carbazoles/pharmacology

KW - Carcinoma, Squamous Cell/drug therapy

KW - Crizotinib/pharmacology

KW - Genetic Testing

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Male

KW - Middle Aged

KW - Oncogene Proteins, Fusion/antagonists & inhibitors

KW - Patient Selection

KW - Piperidines/pharmacology

KW - Smoking/adverse effects

KW - Treatment Outcome

U2 - 10.1007/s00280-018-3571-2

DO - 10.1007/s00280-018-3571-2

M3 - Article

C2 - 29610932

SN - 0344-5704

VL - 81

SP - 965

EP - 968

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Abstract

Keywords

Access to Document

Fingerprint

Cite this